Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 162 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: PSC Clear all
Active, not recruiting Not applicable Interventional

Impact of Lp299v on Vascular Function in Patients With PASC

NCT05227170
View directory record Official record
Conditions
COVID-19
Interventions
Lactobacillus Plantarum 299v Freeze Dried Capsule, Freeze Dried Potato Starch Capsule
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 89 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 25, 2026, 7:47 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2

NCT05040659
View directory record Official record
Conditions
Anosmia, Asymptomatic COVID-19, COVID-19 Respiratory Infection, Influenza, Healthy, PASC Post Acute Sequelae of COVID 19
Interventions
AROMHA Longitudinal Smell Test
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 25, 2026, 7:47 PM EDT
Completed Phase 1 Interventional

Treatment of IgG4-Related Disease With Revlimid and Rituximab

NCT02705638
View directory record Official record
Conditions
Immunoglobulin G Subclass 4 Related Disease, IgG4-related Disease, Autoimmune Pancreatitis, IgG4-related Sclerosing Cholangitis, Retroperitoneal Fibrosis
Interventions
Rituximab, Lenalidomide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Oct 25, 2026, 7:47 PM EDT
Completed Not applicable Interventional

RECOVER-ENERGIZE Platform Protocol_Appendix A (Exercise Intolerance)

NCT06404060
View directory record Official record
Conditions
Long COVID, Long Covid19, Long Covid-19
Interventions
Personalized Cardiopulmonary Rehabilitation, Education
Behavioral · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 25, 2026, 7:47 PM EDT
Completed Phase 1 Interventional

A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833

NCT00001302
View directory record Official record
Conditions
Breast Cancer, Kidney Neoplasm, Lymphoma, Neoplasm Metastasis, Ovarian Cancer
Interventions
PSC 833
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 25, 2026, 7:47 PM EDT
Completed Phase 2 Interventional

RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD)

NCT06404112
View directory record Official record
Conditions
Long COVID, Long COVID-19, Sleep Disturbance
Interventions
Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo
Drug · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 25, 2026, 7:47 PM EDT
Recruiting No phase listed Observational

MRI Based Biomarkers in Pediatric Autoimmune Liver Disease

NCT03175471
View directory record Official record
Conditions
Autoimmune Liver Disease, Primary Sclerosing Cholangitis, Autoimmune Hepatitis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 23 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 25, 2026, 7:47 PM EDT
Completed Phase 1Phase 2 Interventional

Zofin to Treat COVID-19 Long Haulers

NCT05228899
View directory record Official record
Conditions
COVID-19
Interventions
Zofin, Placebo
Drug · Other
Lead sponsor
ZEO ScientifiX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Newport Beach, California • North Hollywood, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 25, 2026, 7:47 PM EDT
Recruiting Not applicable Interventional

Heat thErapy And mobiLity in COVID-19 Survivors

NCT06928116
View directory record Official record
Conditions
Long COVID
Interventions
Heat therapy, Sham Control, Walking
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
50 Years to 90 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 7:47 PM EDT
Completed No phase listed Observational

Treatment Outcomes in PASC Patients With Neurocognitive Impairment

NCT07090564
View directory record Official record
Conditions
Long COVID
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 25, 2026, 7:47 PM EDT
Completed Not applicable Interventional

A Pilot Study Examining Diet in Primary Sclerosing Cholangitis

NCT04678219
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Dietary Intervention
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 25, 2026, 7:47 PM EDT
Completed Phase 2 Interventional

RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)

NCT06404099
View directory record Official record
Conditions
Long COVID, Long COVID-19, Hypersomnia
Interventions
Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 25, 2026, 7:47 PM EDT
Recruiting Phase 2 Interventional

Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation

NCT06940609
View directory record Official record
Conditions
Long COVID, Long COVID Syndrome, Long COVID-19 Syndrome, PASC, PASC Post Acute Sequelae of COVID 19
Interventions
accelerated intermittent theta burst stimulation
Device
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 25, 2026, 7:47 PM EDT
Active, not recruiting No phase listed Observational

Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 (PASC) Using TSPO Positron Emission Tomography (PET) and MRI

NCT05615415
View directory record Official record
Conditions
Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection
Interventions
PET Tracer, MRI Tracer, 3T PET/MRI
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 25, 2026, 7:47 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Study Of Ursolic Acid For Primary Sclerosing Cholangitis

NCT03216876
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Ursolic acid
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 25, 2026, 7:47 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Biobank for Cholestatic Liver Diseases.

NCT03445585
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, Cholangiocarcinoma, Liver Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
9,150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2050
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 25, 2026, 7:47 PM EDT
Completed Phase 1 Interventional

A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer

NCT00001570
View directory record Official record
Conditions
Kidney Neoplasms, Neoplasm Metastasis
Interventions
PSC 833, vinblastine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 25, 2026, 7:47 PM EDT
Completed Not applicable Interventional

RECOVER-ENERGIZE Platform Protocol

NCT06404047
View directory record Official record
Conditions
Long COVID, Long Covid19, Long Covid-19
Interventions
Personalized Cardiopulmonary Rehabilitation, Structured Pacing, Education, Usual Care
Behavioral · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 25, 2026, 7:47 PM EDT
Enrolling by invitation Phase 2 Interventional

DMSO Dual-Route Therapy for Refractory Tinnitus in Long-COVID and Post-COVID-19 Vaccine Injury

NCT07567274
View directory record Official record
Conditions
Tinnitus
Interventions
DMSO-based otic solution with betahistine, dexamethasone, and lidocaine, DMSO-based transdermal cream with levocarnitine and N-acetylcysteine
Drug
Lead sponsor
Leading Edge Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 25, 2026, 7:47 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis

NCT07387549
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Elafibranor, Placebo
Drug · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
69
States / cities
Chandler, Arizona • Phoenix, Arizona • Coronado, California + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 25, 2026, 7:47 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

NCT04480840
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
PLN-74809, Placebo
Drug
Lead sponsor
Pliant Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
21
States / cities
Pasadena, California • Redwood City, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 25, 2026, 7:47 PM EDT
Recruiting Phase 1 Interventional

A Study of SIPLIZUMAB in AILD and LT Patients

NCT06455280
View directory record Official record
Conditions
Autoimmune Liver Disease, Liver Transplant Disorder, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, End Stage Liver DIsease, Cirrhosis, Liver
Interventions
Siplizumab
Drug
Lead sponsor
Elizabeth C. Verna
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 25, 2026, 7:47 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

NCT05833217
View directory record Official record
Conditions
Long COVID, Insulin Resistance, Insulin Sensitivity
Interventions
Adipose Tissue Biopsy, Steady State Plasma Glucose (SSPG) Test
Procedure · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 25, 2026, 7:47 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

NCT05525520
View directory record Official record
Conditions
Pruritus
Interventions
EP547, Placebo
Drug
Lead sponsor
Escient Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Coronado, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 25, 2026, 7:47 PM EDT